Trial Profile

A Phase I, Open-Label Multicenter Study of AM003 Dose Escalation, Administered Intratumorally to Patients With Locally Advanced and Metastatic Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AM 003 (Primary)
Indications Colorectal cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Skin cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer
Focus Adverse reactions; First in man
Sponsors Aummune

Most Recent Events

07 Nov 2024 According to an Aummune media release, data from the study will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Conference, taking place in Houston, Texas.
07 Nov 2024 Status changed from active, no longer recruiting to completed.
07 Nov 2024 Results published in the Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com